{
  "hash": "8370da7963d2c23875e3fab8d042ed0b",
  "result": {
    "engine": "jupyter",
    "markdown": "---\ntitle: \"Cervical Cancer Risk Prediction\"\nsubtitle: \"INFO 523 - Summer 2025 - Final Project\"\nauthor: \"Team Okhawere\"\ntitle-slide-attributes:\n  data-background-image: images/Cervical CA Image.png\n  data-background-size: contain\n  data-background-position: \"100% 50%\"\n  data-background-opacity: \"0.9\"\n  data-slide-number: none\nformat:\n  revealjs: \n     theme:  ['data/customtheming.scss']\n     logo:   Cervical CA image 2.png\n     footer: \"INFO 523 Final Project | Kennedy\"\n     transition: fade\n     slide-number: true\n     autoSlide: 0\neditor: visual\njupyter: python3\nexecute:\n  echo: false\n---\n\n\n# Introduction\n\n-   Cervical cancer is preventable but persists where vaccination/screening access is limited\n\n-   We evaluate whether non-invasive history (demographics, sexual/reproductive history, contraception, smoking, STDs) can triage patients at higher risk of biopsy-positive disease\n\n## Research Questions\n\n-   Can we accurately predict cervical cancer biopsy outcomes using only non-invasive risk factors and lifestyle history?\n\n-   Which factor contribute the most to cervical cancer risk?\n\n# Data\n\n-   The dataset was collected at 'Hospital Universitario de Caracas' in Caracas, Venezuela.\n\n::: {#cell-load-data .cell message='false' execution_count=2}\n\n::: {.cell-output .cell-output-stdout}\n```\nRows: 858  |  Positives (Biopsy=1): 6.4%\n```\n:::\n\n::: {.cell-output .cell-output-display}\n![](presentation_files/figure-revealjs/load-data-output-2.png){#load-data}\n:::\n:::\n\n\n# Modeling\n\n## Baseline Model - Reported CV means (Average Precision)\n\n::: {#18d6e9a0 .cell execution_count=3}\n\n::: {.cell-output .cell-output-display}\n![](presentation_files/figure-revealjs/cell-4-output-1.png){}\n:::\n:::\n\n\n## Validation Leaderbaord (Average Precision)\n\n::: {#ea7c692d .cell execution_count=4}\n\n::: {.cell-output .cell-output-display}\n![](presentation_files/figure-revealjs/cell-5-output-1.png){}\n:::\n:::\n\n\n## Test Evaluation (XGBoost Model)\n\n::: {#6dae200e .cell execution_count=5}\n\n::: {.cell-output .cell-output-display}\n![](presentation_files/figure-revealjs/cell-6-output-1.png){}\n:::\n\n::: {.cell-output .cell-output-stdout}\n```\n\nPR-AUC: 0.145 | ROC-AUC: 0.629\nRecall (Sens): 0.364 | Specificity: 0.814\nPrecision (PPV): 0.121 | Accuracy: 0.784\n```\n:::\n:::\n\n\n## Feature Importance (SHAP Analysis)\n\n:::: columns\n::: {.column width=\"60%\"}\n-   Hormonal Contraceptives (years) was the strongest driver. High values tend to increase predicted risk.\n-   STDs: Number of diagnoses — more diagnoses push predictions up.\n-   Years since first intercourse — longer history generally increases risk.\n-   Age: older age trends up.\n-   STD :Time since last diagnosis — more recent STD tend to increase risk.\n-   Number of pregnancies increase the risk\n:::\n::::\n\n# Conclusion\n\n-   The model is not a definitive diagnostic tool but rather a triage aid to prioritize patients for further screening\n-   **Future Work:**\n    -   The model's performance could be improved with a larger, more balanced dataset\n    -   Implementing a cost-sensitive learning approach could penalize misclassifying positive cases more heavily\n    -   Additional feature engineering and domain expertise could further enhance predictive power\n\n## Limitations\n\n-   Lack of Generalizability\n-   Modest Sensitivity (Recall)\n-   Moderate Predictive Power: Low ROC-AUC\n-   Data Imbalance: Despite using SMOTE\n-   Limited Feature Set\n\n",
    "supporting": [
      "presentation_files"
    ],
    "filters": [],
    "includes": {}
  }
}